Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia. The IMVT stock yearly return is shown above.
The yearly return on the IMVT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMVT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|